熱門資訊> 正文
Personis报告肺癌试验数据
2025-09-04 05:31
- Personalis(PSNL) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Personalis (NASDAQ:PSNL) has shared new results from a late-stage trial conducted by AstraZeneca (AZN) focused on lung cancer.
- The results indicate that Personalis’ advanced molecular residual disease test, known as NeXT Personal, effectively predicts outcomes for patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer who are undergoing neoadjuvant therapy.
- Additionally, it said that the negative result for minimal residual disease before surgery, as well as clearing MRD on the NeXT Personal test, is linked to significant pathological responses in these patients.
More on Personalis
- Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
- Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks
- Personalis gains as VA awards work order worth up to $13.5M
- Personalis outlines $70M–$80M revenue target for 2025 amid 59% sequential clinical test growth and revised biopharma outlook
- Seeking Alpha’s Quant Rating on Personalis
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
